Dr. Robert Zweigerdt (left) and Professor Dr. Nico Lachmann with a bioreactor...
Dr. Robert Zweigerdt (left) and Professor Dr. Nico Lachmann with a bioreactor in the laboratory

© Karin Kaiser/MHH

News • Research collaboration

'Cells of the future' might cure lung infections

Healing the body with cells – this is the ambitious goal of scientists at Hannover Medical School (MHH).

With this in mind, Professor Dr. Nico Lachmann and Dr. Robert Zweigerdt have initiated a research collaboration and license agreement with the pharmaceutical company Novo Nordisk A/S, to combine academic knowhow with the translational power of the industry. The overall aim of the endeavor is to use special stem cells for developing advanced therapies to regenerate failing organs and cure diseases, for which no adequate treatment is currently available. The collaboration agreement was supported by the technology transfer agency Ascenion.

The project relies on so-called induced pluripotent stem cells (iPS cells), which can be obtained from patients’ somatic cells by a technology known as “somatic cell reprogramming”. The special feature of the resulting iPS cells is their ability to give rise to any functional cell type of the human body. Thus, iPS cells can be used to generate specific replacement cells in a dish, which subsequently can be returned to a patient as a cure.

Recommended article

MHH scientists have recently enabled continuous production of iPS cell-derived functional blood cells, including macrophages (phagocytes), by using special bioreactors. "Within the framework of the new research collaboration, we are now specifically developing this technique further, to enable a potential use of these macrophages therapeutically and eventually aiming for the first application in a clinical study. So far, there has been no clinical application of iPS cell progenies in Germany," explains Professor Lachmann.

In pre-clinical proof-of-concept experiments, MHH researchers have readily shown that the iPS cells-macrophages have a prominent therapeutic potential to eliminate disease-causing bacteria. Therefore, they have the great potential, for example, for treating patients with severe bacterial infection of the lungs (pneumonia), which do not respond to antibiotics. "The concept of therapeutic application of iPS cell-derived progenies is already about 15 years old. I am very pleased that we can now advance this idea towards real therapies," says Dr. Zweigerdt. 


Source: Hannover Medical School (MHH)

17.02.2021

Read all latest stories

Related articles

Photo

News • Infectious disease screening

Bronchial organoids and drug discovery applications advance Covid-19 research

A research group from Kyoto developed two in vitro models to study SARS-CoV-2, and showed that they can be used for drug screening for infectious diseases including Covid-19.

Photo

News • Immunological memory

How our lungs 'remember' a Covid-19 infection

After infection with SARS-CoV-2, where does the immune system store the memory to provide long-term protection against reinfection? Though numerous studies have examined blood to track immune…

Photo

News • Respiratory research

Covid-19 infection does not affect lung function in kids, young adults

Covid-19 infection does not appear to affect the lung function of young adults, according to new research presented at the ‘virtual’ European Respiratory Society International Congress. In the…

Related products

Associates of Cape Cod – Fungitell STAT Assay

Identification/Susceptibility

Associates of Cape Cod – Fungitell STAT Assay

Associates of Cape Cod Europe GmbH
Hologic – Novodiag System

Automation & sample processing

Hologic – Novodiag System

Hologic, Inc.
Lifotronic - FA-160 Immunofluorescence Analyzer

Immunoassays

Lifotronic - FA-160 Immunofluorescence Analyzer

Lifotronic Technology Co., Ltd
medigration – ImageVision

Reading

medigration – ImageVision

medigration GmbH
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Subscribe to Newsletter